» Articles » PMID: 13832218

Results of a Study of the Reactogenic and Immunogenic Properties of Live Anti-poliomyelitis Vaccine

Overview
Specialty Public Health
Date 1959 Jan 1
PMID 13832218
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The authors have studied the harmlessness and immunogenic properties of live poliomyelitis vaccine made in Leningrad from Sabin strains of low pathogenicity for monkeys. More than 20 000 children of pre-school (6 months to 3 years) and school age (7-14 years) were each given 100 000 tissue-culture infective doses of virus of types 1, 2 and 3, injected either in three stages at monthly intervals in the form of monovaccines, or in two stages, a monovaccine of type 1 being followed after a month's interval by injection of a divalent vaccine of types 2 and 3. The vaccination caused no symptoms of lesions of the central nervous system or other organs. In the blood of the inoculated children there was a regular build-up of virus-neutralizing antibodies to the serotypes mentioned, the intensity of which depended on the antibody level before vaccination and was in a constant relationship to the multiplication of the virus in the intestinal canal. The antibody titre was maintained at high levels for 6-9 months after immunization and fell a little after 12-18 months. The vaccinal virus is easily transferred from vaccinated children to contact groups, which are gradually vaccinated by this natural means.Lengthy and numerous passages of vaccinal strains through the intestinal canal of normal, susceptible children showed that strains may periodically appear which have a higher neurotropic activity for monkeys. This activity, however, did not increase in subsequent passage and returned to the initial level.

Citing Articles

Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity.

Pacheco-Garcia U, Serafin-Lopez J Vaccines (Basel). 2023; 11(3).

PMID: 36992239 PMC: 10055900. DOI: 10.3390/vaccines11030655.


Why are vaccines against many human viral diseases still unavailable; an historic perspective?.

Tannock G, Kim H, Xue L J Med Virol. 2019; 92(2):129-138.

PMID: 31502669 PMC: 7166819. DOI: 10.1002/jmv.25593.


Virus excretion after mass vaccination with attenuated polioviruses in Hungary.

DOMOK I, Molnar E, Jancso A Br Med J. 1961; 1(5237):1410-7.

PMID: 13723659 PMC: 1953969. DOI: 10.1136/bmj.1.5237.1410.


Antipoliomyelitis neutralizing antibodies in maternal and neonatal serum.

Tanzi M, Colotto P, Vignali M, Affanni P, Bracchi U, Bellelli E Eur J Epidemiol. 1997; 13(5):559-65.

PMID: 9258569 DOI: 10.1023/a:1007345930234.


Factors affecting the efficacy of live poliovirus vaccine in warm climates. Efficacy of type 1 Sabin vaccine administered together with antihuman gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda.

DOMOK I, Balayan M, Fayinka O, SKRTIC N, Soneji A, HARLAND P Bull World Health Organ. 1974; 51(4):333-47.

PMID: 4142936 PMC: 2366300.

References
1.
Sabin A . Characteristics and genetic potentialities of experimentally produced and naturally occurring variants of poliomyelitis virus. Ann N Y Acad Sci. 1955; 61(4):924-38; discussion, 938-9. DOI: 10.1111/j.1749-6632.1955.tb42551.x. View

2.
Flack A, Hummeler K, HUNT Jr A, JERVIS G, KOPROWSKI H, NORTON T . Immunization of infants with living attenuated poliomyelitis virus; laboratory investigations of alimentary infection and antibody response in infants under six months of age with congenitally acquired antibodies. J Am Med Assoc. 1956; 162(14):1281-8. View

3.
Sabin A . Present status of attenuated live-virus poliomyelitis vaccine. J Am Med Assoc. 1956; 162(18):1589-96. DOI: 10.1001/jama.1956.02970350005002. View

4.
Sabin A . Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc. 1957; 164(11):1216-23. DOI: 10.1001/jama.1957.62980110008008. View